Novocure Secures Early FDA Approval for Optune Pax, Shares Rise 4.7%
Novocure received early FDA approval for Optune Pax in locally advanced pancreatic cancer after PANOVA-3 showed median overall survival of 16.2 versus 14.2 months and a one-year survival of 68.1% versus 60.2%. Shares jumped 4.7% after approval but are down 8.1% in six months versus the industry’s 21.2% gain.
1. FDA Approval Accelerated Timeline
Novocure obtained FDA approval for Optune Pax to treat adult patients with locally advanced pancreatic cancer in combination with gemcitabine and nab-paclitaxel, beating the anticipated second-quarter 2026 timeline.
2. PANOVA-3 Efficacy Data
The phase III PANOVA-3 trial demonstrated that Optune Pax plus gemcitabine and nab-paclitaxel extended median overall survival to 16.2 months versus 14.2 months with chemotherapy alone and improved one-year survival from 60.2% to 68.1%, while also delaying pain progression.
3. Market and Revenue Potential
The pancreatic cancer treatment market is projected to grow from $3.01 billion to $9.57 billion by 2034 at a 13.7% CAGR, presenting significant top-line expansion opportunity for Optune Pax in a space with limited systemic options.
4. Stock Performance
Since FDA approval on February 11, Novocure shares have risen 4.7%, but they remain down 8.1% over the past six months compared with a 21.2% industry gain and an 8.1% rise in the S&P 500.